Novartis released promising interim Phase II data of iptacopan in C3 glomerulopathy (C3G) at the virtual American Society of Nephrology 2020 Annual Meeting.
The European medicines watchdog recommended approving AstraZeneca’s treatments for a form of heart failure and a lung disorder, the British drugmaker said.
Swiss drugmaker Novartis grabbed a key European panel’s recommendation for Leqvio, clearing the way for the prospective cholesterol drug’s approval in the next couple of months.
Inventiva, with headquarters in Daix, France, received Breakthrough Therapy designation from the U.S. Food and Drug Administration for the company’s lanifibranor for nonalcoholic steatohepatitis (NASH).
Pfizer and Opko Health reported their Phase III clinical trial of somatrogan met the primary endpoint compared to Genotropin (somatropin) for treating children 3 to 18 years of age with growth hormone deficiency (GHD).
The European health regulator is reviewing a Covid-19 vaccine being developed by Pfizer and BioNTech in real time, days after launching a similar assessment process for AstraZeneca’s vaccine.
A vaccine against Covid-19 may be ready by year-end, the head of the World Health Organization (WHO) said, without elaborating.
The European Medicines Agency (EMA) recommended approval for Lynparza in patients with a form of prostate cancer and as a first-line maintenance treatment for a form of advanced ovarian cancer, the British drugmaker AstraZeneca said.
Europe’s healthcare regulator endorsed using dexamethasone to treat Covid-19 patients with breathing difficulties, paving the way for the steroid to become the region’s second approved treatment for the respiratory illness.
bluebird bio Inc. announced updated results from the clinical development program for the company’s investigational elivaldogene autotemcel (eli-cel, Lenti-D) gene therapy in patients with cerebral adrenoleukodystrophy (CALD), including long-term results from the Phase 2/3 Starbeam study and data from the Phase 3 ALD-104 study.